Lorenzo B.
- Country
- Italy
- Department
- Medicina Generale - Immunologia e Allergologia
Research Overview
- Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Long-Term Safety and Tolerability Assessment of Dapirolizumab Pegol in Patients with Systemic Lupus Erythematosus: A Multicenter, Open-Label Extension Study
Data & Insights
Has run more than one trial at 132 of 223 partner sites.
Specializations
Autoimmune Disorders
This investigator specializes in treating complex autoimmune conditions, with particular emphasis on Systemic Lupus Erythematosus (SLE) and Sjögren's Syndrome.
- Moderate to severe systemic manifestations
- Long-term disease management
- Treatment-resistant cases
The investigator's work focuses on evaluating novel therapeutic approaches for patients with challenging disease presentations.
Therapeutic Innovation
The investigator conducts research on innovative treatments including dazodalibep and dapirolizumab pegol for autoimmune conditions.
- Novel biological therapies
- Add-on treatment strategies
- Safety and efficacy evaluation
Their work encompasses the assessment of emerging therapeutic options for patients with inadequate response to standard treatments.
Treatment Optimization
The investigator explores steroid management strategies and alternative therapeutic approaches in autoimmune diseases.
- Glucocorticoid withdrawal protocols
- Standard-of-care optimization
- Long-term disease control
Their research aims to improve treatment outcomes while minimizing medication-related complications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.